

ABSTRACT

The present invention provides a compound represented by the formula (1):



(1)

wherein X^a and Y^a are each a single bond and the like,
cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7 - 30 amino acid residues,
R^1 is a hydrogen atom, a group represented by the formula (2):



(2)

wherein X^b and Y^b are each a single bond and the like,
cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7 - 30 amino acid residues, or cancer antigen peptide C, and
cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7 - 30 amino acid residues containing one cysteine residue,
or a salt thereof, and the like.